Does Rallies show 13F holders for ACET?

Yes. Rallies tracks hedge fund and 13F ownership data for ACET, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ACET research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ACET. It does not provide personalized investment advice.

ACET (Adicet Bio, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Adicet Bio, Inc. Common Stock (ACET) is a publicly traded Healthcare sector company. As of May 21, 2026, ACET trades at $7.95 with a market cap of $70.11M and a P/E ratio of -0.79. ACET moved +7.59% today. Year to date, ACET is -4.79%; over the trailing twelve months it is -35.28%. Its 52-week range spans $6.01 to $24.64. Analyst consensus is strong buy with an average price target of $34.83. Rallies surfaces ACET's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ACET stock?

Hedge funds tracked by Rallies that own ACET include Orbimed Advisors and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Adicet Bio, Inc. Common Stock.

ACET Key Metrics

Key financial metrics for ACET
Metric	Value
Price	$7.95
Market Cap	$70.11M
P/E Ratio	-0.79
EPS	$-9.80
Dividend Yield	0.00%
52-Week High	$24.64
52-Week Low	$6.01
Volume	0
Avg Volume	0
Revenue (TTM)	$682.93M
Net Income	$-346.15M
Gross Margin	12.76%

Top Hedge Funds Holding ACET

Orbimed Advisors holds 1.03M shares of ACET, changed +0.00% as of Mar 31, 2026.
Panagora Asset holds 23.19K shares of ACET, changed -55.18% as of Mar 31, 2024.

Latest ACET News

Adicet Bio doubles prula-cel enrollment to 20+ patients, secures $74.8M and FDA outpatient dosing — Jan 7, 2026

Recent ACET Insider Trades

ORBIMED ADVISORS LLC sold 32.52K (~$204.57K) on Apr 8, 2026.
ORBIMED ADVISORS LLC sold 40.42K (~$263.51K) on Apr 8, 2026.
ORBIMED ADVISORS LLC sold 29.32K (~$191.45K) on Apr 7, 2026.

ACET Analyst Consensus

7 analysts cover ACET: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $34.83.

Common questions about ACET

Who owns ACET stock?: Hedge funds tracked by Rallies that own ACET include Orbimed Advisors and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Adicet Bio, Inc. Common Stock.
Does Rallies show 13F holders for ACET?: Yes. Rallies tracks hedge fund and 13F ownership data for ACET, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ACET research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ACET. It does not provide personalized investment advice.